XML 312 R119.htm IDEA: XBRL DOCUMENT v3.22.0.1
Geographic and Segment Information (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended 63 Months Ended
Dec. 02, 2020
USD ($)
Nov. 30, 2019
USD ($)
Dec. 31, 2021
USD ($)
geographic_region
Sep. 30, 2021
USD ($)
Jun. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Sep. 30, 2020
USD ($)
Jun. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2021
USD ($)
segment
geographic_region
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2020
USD ($)
Segment Reporting Information [Line Items]                            
Number of reportable segments | segment                     3      
Number of geographic regions in which entity operates | geographic_region     3               3      
Net sales     $ 270,064 $ 253,215 $ 264,483 $ 247,603 $ 269,555 $ 240,083 $ 182,206 $ 242,397 $ 1,035,365 $ 934,241 [1] $ 1,084,170 [1]  
Reportable segments income (loss) before income taxes                     36,183 (220,683) (95,468)  
Operating loss from continuing operations     24,754 $ 16,422 $ (36,262) $ (5,698) (249,023) $ (7,552) $ (16,743) $ (581) (784) (273,899) [1] (171,554) [1]  
Interest income                     435 131 [1] 803 [1]  
Interest expense                     (50,151) (40,837) [1] (15,091) [1]  
Loss on debt extinguishment                     (60,238) (1,407) [1],[2] 0 [1],[2]  
Foreign exchange and other gains/(losses)                     (13,734) (32,010) [1] (2,536) [1]  
Loss from continuing operations before tax                     (124,472) (348,022) [1] (188,378) [1]  
Litigation provision, net                       0 0  
Impairment of long-lived assets   $ 89,000                 0 6,762 [2] 142,517 [2]  
Impairment of disposal group and loss on sale                     0 180,160 [1] 0 [1]  
Impairment of goodwill $ 21,300 $ 42,400                 0 21,269 [1],[2] 42,417 [1],[2] $ 63,700
Decommissioning provision                       0 0  
Total Assets     2,200,951       2,399,961 [3]       2,200,951 2,399,961 [3]   2,399,961 [3]
Capital expenditures                     22,313 35,916 27,977  
Heart Valves                            
Segment Reporting Information [Line Items]                            
Impairment of disposal group and loss on sale                       180,200    
Impairment of goodwill                       21,300    
Caisson Interventional LLC                            
Segment Reporting Information [Line Items]                            
Impairment of long-lived assets                         89,000  
Impairment of goodwill                         42,400  
ImThera                            
Segment Reporting Information [Line Items]                            
Impairment of long-lived assets                         50,300  
Continuing Operations                            
Segment Reporting Information [Line Items]                            
Other expenses                     36,967 53,216 76,086  
Cardiopulmonary                            
Segment Reporting Information [Line Items]                            
Litigation provision, net                     38,100 3,900 (600)  
United States                            
Segment Reporting Information [Line Items]                            
Net sales                     571,299 468,634 546,484  
Europe                            
Segment Reporting Information [Line Items]                            
Net sales                     201,525 193,367 223,183  
Rest of World                            
Segment Reporting Information [Line Items]                            
Net sales                     262,541 272,240 314,503  
United Kingdom                            
Segment Reporting Information [Line Items]                            
Net sales                     35,800 29,700 37,700  
Saluggia, Italy                            
Segment Reporting Information [Line Items]                            
Litigation provision, net             42,200       39,300 43,000    
Decommissioning provision                       42,200    
Operating Segments | Cardiopulmonary                            
Segment Reporting Information [Line Items]                            
Net sales                     482,979 446,732 504,716  
Impairment of goodwill                       0    
Operating Segments | Cardiopulmonary | Continuing Operations                            
Segment Reporting Information [Line Items]                            
Reportable segments income (loss) before income taxes                     (6,429) 35,735 50,533  
Total Assets     921,481       1,040,318       921,481 1,040,318   1,040,318
Capital expenditures                     14,824 20,975 16,302  
Operating Segments | Neuromodulation                            
Segment Reporting Information [Line Items]                            
Net sales                     456,172 354,444 424,547  
Impairment of goodwill                       0    
Operating Segments | Neuromodulation | Continuing Operations                            
Segment Reporting Information [Line Items]                            
Reportable segments income (loss) before income taxes                     169,499 109,273 83,333  
Total Assets     646,394       673,579       646,394 673,579   673,579
Capital expenditures                     179 7,318 3,415  
Operating Segments | Advanced Circulatory Support                            
Segment Reporting Information [Line Items]                            
Net sales                     55,459 42,321 31,923  
Impairment of goodwill                       0    
Operating Segments | Advanced Circulatory Support | Continuing Operations                            
Segment Reporting Information [Line Items]                            
Reportable segments income (loss) before income taxes                     2,195 (575) 3,941  
Total Assets     231,846       239,404       231,846 239,404   239,404
Capital expenditures                     1,326 733 540  
Operating Segments | United States | Cardiopulmonary                            
Segment Reporting Information [Line Items]                            
Net sales                     154,073 132,543 161,471  
Operating Segments | United States | Neuromodulation                            
Segment Reporting Information [Line Items]                            
Net sales                     358,476 282,509 335,332  
Operating Segments | United States | Advanced Circulatory Support                            
Segment Reporting Information [Line Items]                            
Net sales                     53,821 41,094 30,781  
Operating Segments | Europe | Cardiopulmonary                            
Segment Reporting Information [Line Items]                            
Net sales                     134,562 122,062 135,632  
Operating Segments | Europe | Neuromodulation                            
Segment Reporting Information [Line Items]                            
Net sales                     51,435 39,019 46,262  
Operating Segments | Europe | Advanced Circulatory Support                            
Segment Reporting Information [Line Items]                            
Net sales                     1,120 1,027 741  
Operating Segments | Rest of World | Cardiopulmonary                            
Segment Reporting Information [Line Items]                            
Net sales                     194,344 192,127 207,613  
Operating Segments | Rest of World | Neuromodulation                            
Segment Reporting Information [Line Items]                            
Net sales                     46,261 32,916 42,953  
Operating Segments | Rest of World | Advanced Circulatory Support                            
Segment Reporting Information [Line Items]                            
Net sales                     518 200 401  
Other                            
Segment Reporting Information [Line Items]                            
Net sales                     40,755 90,744 122,984  
Impairment of goodwill                       21,269    
Other | Continuing Operations                            
Segment Reporting Information [Line Items]                            
Reportable segments income (loss) before income taxes                     (129,082) (365,116) (233,275)  
Total Assets     $ 401,230       $ 446,660       401,230 446,660   $ 446,660
Capital expenditures                     5,984 6,890 7,720  
Other | United States                            
Segment Reporting Information [Line Items]                            
Net sales                     4,929 12,488 18,900  
Other | Europe                            
Segment Reporting Information [Line Items]                            
Net sales                     14,407 31,259 40,548  
Other | Rest of World                            
Segment Reporting Information [Line Items]                            
Net sales                     $ 21,419 $ 46,997 $ 63,536  
[1] The consolidated statements of income (loss) for the years ended December 31, 2020 and 2019 have been revised. For further details refer to “Note 1. Nature of Operations.”
[2] The consolidated statements of cash flows for the years ended December 31, 2020 and 2019 have been revised. For further details refer to “Note 1. Nature of Operations.”
[3] The consolidated balance sheet as of December 31, 2020 has been revised. For further details refer to “Note 1. Nature of Operations.”